Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

Josef S. Smolen, Jonathan Kay, Mittie K. Doyle, Robert Landewé, Eric Lawrence Matteson, Jürgen Wollenhaupt, Norman Gaylis, Frederick T. Murphy, Jeffrey S. Neal, Yiying Zhou, Sudha Visvanathan, Elizabeth C. Hsia, Mahboob U. Rahman

Research output: Contribution to journalArticle

390 Citations (Scopus)

Abstract

Background: Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat rheumatoid arthritis, but whether use of a different TNFα inhibitor can improve patient response is unknown. We assess the efficacy and safety of the TNFα inhibitor golimumab in patients with active rheumatoid arthritis who had previously received one or more TNFα inhibitors. Methods: 461 patients with active rheumatoid arthritis from 82 sites in 10 countries were randomly allocated by interactive voice response system, stratified by study site and methotrexate use, to receive subcutaneous injections of placebo (n=155), 50 mg golimumab (n=153), or 100 mg golimumab (n=153) every 4 weeks between Feb 21, 2006, and Sept 26, 2007. Allocation was double-blind. Eligible patients had been treated with at least one dose of a TNFα inhibitor previously. Patients continued stable doses of methotrexate, sulfasalazine, hydroxychloroquine, oral corticosteroids, and non-steroidal anti-inflammatory drugs. The primary endpoint was achievement at week 14 of 20% or higher improvement in American College of Rheumatology criteria for assessment of rheumatoid arthritis (ACR20). At week 16, patients who had less than 20% improvement in tender and swollen joint counts were given rescue therapy and changed treatment from placebo to 50 mg golimumab, or from 50 mg to 100 mg golimumab. Drug efficacy was assessed by intention to treat and safety was assessed according to the study drug given. This study is registered with ClinicalTrials.gov, number NCT00299546. Findings: Patients had discontinued previous TNFα inhibitors because of lack of effectiveness (269 [58%] patients) or reasons unrelated to effectiveness (246 [53%] patients), such as intolerance and accessibility issues. Patients had active disease, which was indicated by a median of 14·0 (IQR 9·0-22·0) swollen and 26·0 (16·0-41·0) tender joints for the whole group. 28 (18%) patients on placebo, 54 (35%) patients on 50 mg golimumab (odds ratio 2·5 [95% CI 1·5-4·2], p=0·0006), and 58 (38%) patients on 100 mg golimumab (2·8 [1·6-4·7], p=0·0001) achieved ACR20 at week 14. Two patients were never treated, and 57 patients did not complete the study because of adverse events, unsatisfactory treatment effect, loss to follow-up, death, or other reasons. 155 patients on placebo, 153 on 50 mg golimumab, and 153 on 100 mg golimumab were assessed for drug efficacy. For weeks 1-16, serious adverse events were recorded in 11 (7%) patients on placebo, 8 (5%) on 50 mg golimumab, and 4 (3%) on 100 mg golimumab. For weeks 1-24, after some patients were given rescue therapy, serious adverse events were recorded in 15 (10%) patients on placebo, 14 (5%) on 50 mg golimumab, and 8 (4%) on 100 mg golimumab. Interpretation: Golimumab reduced the signs and symptoms of rheumatoid arthritis in patients with active disease who had previously received one or more TNFα inhibitors. Funding: Centocor Research and Development and Schering-Plough Research Institute.

Original languageEnglish (US)
Pages (from-to)210-221
Number of pages12
JournalThe Lancet
Volume374
Issue number9685
DOIs
StatePublished - 2009

Fingerprint

Multicenter Studies
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Placebos
Therapeutics
golimumab
Methotrexate
Pharmaceutical Preparations
Joints
Hydroxychloroquine
Safety
Sulfasalazine
Subcutaneous Injections

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study) : a multicentre, randomised, double-blind, placebo-controlled, phase III trial. / Smolen, Josef S.; Kay, Jonathan; Doyle, Mittie K.; Landewé, Robert; Matteson, Eric Lawrence; Wollenhaupt, Jürgen; Gaylis, Norman; Murphy, Frederick T.; Neal, Jeffrey S.; Zhou, Yiying; Visvanathan, Sudha; Hsia, Elizabeth C.; Rahman, Mahboob U.

In: The Lancet, Vol. 374, No. 9685, 2009, p. 210-221.

Research output: Contribution to journalArticle

Smolen, JS, Kay, J, Doyle, MK, Landewé, R, Matteson, EL, Wollenhaupt, J, Gaylis, N, Murphy, FT, Neal, JS, Zhou, Y, Visvanathan, S, Hsia, EC & Rahman, MU 2009, 'Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial', The Lancet, vol. 374, no. 9685, pp. 210-221. https://doi.org/10.1016/S0140-6736(09)60506-7
Smolen, Josef S. ; Kay, Jonathan ; Doyle, Mittie K. ; Landewé, Robert ; Matteson, Eric Lawrence ; Wollenhaupt, Jürgen ; Gaylis, Norman ; Murphy, Frederick T. ; Neal, Jeffrey S. ; Zhou, Yiying ; Visvanathan, Sudha ; Hsia, Elizabeth C. ; Rahman, Mahboob U. / Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study) : a multicentre, randomised, double-blind, placebo-controlled, phase III trial. In: The Lancet. 2009 ; Vol. 374, No. 9685. pp. 210-221.
@article{b64003aea61346ff863a6ceb38d352e6,
title = "Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial",
abstract = "Background: Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat rheumatoid arthritis, but whether use of a different TNFα inhibitor can improve patient response is unknown. We assess the efficacy and safety of the TNFα inhibitor golimumab in patients with active rheumatoid arthritis who had previously received one or more TNFα inhibitors. Methods: 461 patients with active rheumatoid arthritis from 82 sites in 10 countries were randomly allocated by interactive voice response system, stratified by study site and methotrexate use, to receive subcutaneous injections of placebo (n=155), 50 mg golimumab (n=153), or 100 mg golimumab (n=153) every 4 weeks between Feb 21, 2006, and Sept 26, 2007. Allocation was double-blind. Eligible patients had been treated with at least one dose of a TNFα inhibitor previously. Patients continued stable doses of methotrexate, sulfasalazine, hydroxychloroquine, oral corticosteroids, and non-steroidal anti-inflammatory drugs. The primary endpoint was achievement at week 14 of 20{\%} or higher improvement in American College of Rheumatology criteria for assessment of rheumatoid arthritis (ACR20). At week 16, patients who had less than 20{\%} improvement in tender and swollen joint counts were given rescue therapy and changed treatment from placebo to 50 mg golimumab, or from 50 mg to 100 mg golimumab. Drug efficacy was assessed by intention to treat and safety was assessed according to the study drug given. This study is registered with ClinicalTrials.gov, number NCT00299546. Findings: Patients had discontinued previous TNFα inhibitors because of lack of effectiveness (269 [58{\%}] patients) or reasons unrelated to effectiveness (246 [53{\%}] patients), such as intolerance and accessibility issues. Patients had active disease, which was indicated by a median of 14·0 (IQR 9·0-22·0) swollen and 26·0 (16·0-41·0) tender joints for the whole group. 28 (18{\%}) patients on placebo, 54 (35{\%}) patients on 50 mg golimumab (odds ratio 2·5 [95{\%} CI 1·5-4·2], p=0·0006), and 58 (38{\%}) patients on 100 mg golimumab (2·8 [1·6-4·7], p=0·0001) achieved ACR20 at week 14. Two patients were never treated, and 57 patients did not complete the study because of adverse events, unsatisfactory treatment effect, loss to follow-up, death, or other reasons. 155 patients on placebo, 153 on 50 mg golimumab, and 153 on 100 mg golimumab were assessed for drug efficacy. For weeks 1-16, serious adverse events were recorded in 11 (7{\%}) patients on placebo, 8 (5{\%}) on 50 mg golimumab, and 4 (3{\%}) on 100 mg golimumab. For weeks 1-24, after some patients were given rescue therapy, serious adverse events were recorded in 15 (10{\%}) patients on placebo, 14 (5{\%}) on 50 mg golimumab, and 8 (4{\%}) on 100 mg golimumab. Interpretation: Golimumab reduced the signs and symptoms of rheumatoid arthritis in patients with active disease who had previously received one or more TNFα inhibitors. Funding: Centocor Research and Development and Schering-Plough Research Institute.",
author = "Smolen, {Josef S.} and Jonathan Kay and Doyle, {Mittie K.} and Robert Landew{\'e} and Matteson, {Eric Lawrence} and J{\"u}rgen Wollenhaupt and Norman Gaylis and Murphy, {Frederick T.} and Neal, {Jeffrey S.} and Yiying Zhou and Sudha Visvanathan and Hsia, {Elizabeth C.} and Rahman, {Mahboob U.}",
year = "2009",
doi = "10.1016/S0140-6736(09)60506-7",
language = "English (US)",
volume = "374",
pages = "210--221",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9685",

}

TY - JOUR

T1 - Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study)

T2 - a multicentre, randomised, double-blind, placebo-controlled, phase III trial

AU - Smolen, Josef S.

AU - Kay, Jonathan

AU - Doyle, Mittie K.

AU - Landewé, Robert

AU - Matteson, Eric Lawrence

AU - Wollenhaupt, Jürgen

AU - Gaylis, Norman

AU - Murphy, Frederick T.

AU - Neal, Jeffrey S.

AU - Zhou, Yiying

AU - Visvanathan, Sudha

AU - Hsia, Elizabeth C.

AU - Rahman, Mahboob U.

PY - 2009

Y1 - 2009

N2 - Background: Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat rheumatoid arthritis, but whether use of a different TNFα inhibitor can improve patient response is unknown. We assess the efficacy and safety of the TNFα inhibitor golimumab in patients with active rheumatoid arthritis who had previously received one or more TNFα inhibitors. Methods: 461 patients with active rheumatoid arthritis from 82 sites in 10 countries were randomly allocated by interactive voice response system, stratified by study site and methotrexate use, to receive subcutaneous injections of placebo (n=155), 50 mg golimumab (n=153), or 100 mg golimumab (n=153) every 4 weeks between Feb 21, 2006, and Sept 26, 2007. Allocation was double-blind. Eligible patients had been treated with at least one dose of a TNFα inhibitor previously. Patients continued stable doses of methotrexate, sulfasalazine, hydroxychloroquine, oral corticosteroids, and non-steroidal anti-inflammatory drugs. The primary endpoint was achievement at week 14 of 20% or higher improvement in American College of Rheumatology criteria for assessment of rheumatoid arthritis (ACR20). At week 16, patients who had less than 20% improvement in tender and swollen joint counts were given rescue therapy and changed treatment from placebo to 50 mg golimumab, or from 50 mg to 100 mg golimumab. Drug efficacy was assessed by intention to treat and safety was assessed according to the study drug given. This study is registered with ClinicalTrials.gov, number NCT00299546. Findings: Patients had discontinued previous TNFα inhibitors because of lack of effectiveness (269 [58%] patients) or reasons unrelated to effectiveness (246 [53%] patients), such as intolerance and accessibility issues. Patients had active disease, which was indicated by a median of 14·0 (IQR 9·0-22·0) swollen and 26·0 (16·0-41·0) tender joints for the whole group. 28 (18%) patients on placebo, 54 (35%) patients on 50 mg golimumab (odds ratio 2·5 [95% CI 1·5-4·2], p=0·0006), and 58 (38%) patients on 100 mg golimumab (2·8 [1·6-4·7], p=0·0001) achieved ACR20 at week 14. Two patients were never treated, and 57 patients did not complete the study because of adverse events, unsatisfactory treatment effect, loss to follow-up, death, or other reasons. 155 patients on placebo, 153 on 50 mg golimumab, and 153 on 100 mg golimumab were assessed for drug efficacy. For weeks 1-16, serious adverse events were recorded in 11 (7%) patients on placebo, 8 (5%) on 50 mg golimumab, and 4 (3%) on 100 mg golimumab. For weeks 1-24, after some patients were given rescue therapy, serious adverse events were recorded in 15 (10%) patients on placebo, 14 (5%) on 50 mg golimumab, and 8 (4%) on 100 mg golimumab. Interpretation: Golimumab reduced the signs and symptoms of rheumatoid arthritis in patients with active disease who had previously received one or more TNFα inhibitors. Funding: Centocor Research and Development and Schering-Plough Research Institute.

AB - Background: Tumour necrosis factor α (TNFα) inhibitors are frequently used to treat rheumatoid arthritis, but whether use of a different TNFα inhibitor can improve patient response is unknown. We assess the efficacy and safety of the TNFα inhibitor golimumab in patients with active rheumatoid arthritis who had previously received one or more TNFα inhibitors. Methods: 461 patients with active rheumatoid arthritis from 82 sites in 10 countries were randomly allocated by interactive voice response system, stratified by study site and methotrexate use, to receive subcutaneous injections of placebo (n=155), 50 mg golimumab (n=153), or 100 mg golimumab (n=153) every 4 weeks between Feb 21, 2006, and Sept 26, 2007. Allocation was double-blind. Eligible patients had been treated with at least one dose of a TNFα inhibitor previously. Patients continued stable doses of methotrexate, sulfasalazine, hydroxychloroquine, oral corticosteroids, and non-steroidal anti-inflammatory drugs. The primary endpoint was achievement at week 14 of 20% or higher improvement in American College of Rheumatology criteria for assessment of rheumatoid arthritis (ACR20). At week 16, patients who had less than 20% improvement in tender and swollen joint counts were given rescue therapy and changed treatment from placebo to 50 mg golimumab, or from 50 mg to 100 mg golimumab. Drug efficacy was assessed by intention to treat and safety was assessed according to the study drug given. This study is registered with ClinicalTrials.gov, number NCT00299546. Findings: Patients had discontinued previous TNFα inhibitors because of lack of effectiveness (269 [58%] patients) or reasons unrelated to effectiveness (246 [53%] patients), such as intolerance and accessibility issues. Patients had active disease, which was indicated by a median of 14·0 (IQR 9·0-22·0) swollen and 26·0 (16·0-41·0) tender joints for the whole group. 28 (18%) patients on placebo, 54 (35%) patients on 50 mg golimumab (odds ratio 2·5 [95% CI 1·5-4·2], p=0·0006), and 58 (38%) patients on 100 mg golimumab (2·8 [1·6-4·7], p=0·0001) achieved ACR20 at week 14. Two patients were never treated, and 57 patients did not complete the study because of adverse events, unsatisfactory treatment effect, loss to follow-up, death, or other reasons. 155 patients on placebo, 153 on 50 mg golimumab, and 153 on 100 mg golimumab were assessed for drug efficacy. For weeks 1-16, serious adverse events were recorded in 11 (7%) patients on placebo, 8 (5%) on 50 mg golimumab, and 4 (3%) on 100 mg golimumab. For weeks 1-24, after some patients were given rescue therapy, serious adverse events were recorded in 15 (10%) patients on placebo, 14 (5%) on 50 mg golimumab, and 8 (4%) on 100 mg golimumab. Interpretation: Golimumab reduced the signs and symptoms of rheumatoid arthritis in patients with active disease who had previously received one or more TNFα inhibitors. Funding: Centocor Research and Development and Schering-Plough Research Institute.

UR - http://www.scopus.com/inward/record.url?scp=67650379733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650379733&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(09)60506-7

DO - 10.1016/S0140-6736(09)60506-7

M3 - Article

C2 - 19560810

AN - SCOPUS:67650379733

VL - 374

SP - 210

EP - 221

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9685

ER -